MOLOGEN AG: Patent for DNA based vaccine against important cat disease granted

The European Patent Office has informed MOLOGEN AG (ISIN DE0006637200), that the patent for the DNA-vaccine against oncoviruses was granted. Corresponding applications outside the European Union are pending before national patent offices.

The invention relates to a DNA-vaccine against oncoviruses, based on MOLOGEN’s proprietary DNA-vector MIDGE-TH1. Oncoviruses cause severe diseases including cancer, anaemia and immuno-suppression. Especially cats can be protected against infections with the oncovirus FeLV (Feline Leukemia Virus) by the vaccine.

FeLV is a feline virus infecting cats worldwide. Serious diseases following infection are a major cause for death of cats. Currently, approximately 10 % of all cats in Europe, USA and Japan, the most important markets for veterinary pharmaceuticals for pets, are infected with the virus.

Today, an effective therapy for FeLV infections is not available. In best case scenario, the disease can be suppressed for a certain time. Several chemotherapeutics are applicable in cats, but side effects are as serious as in applications for humans. The only effective way to prevent FeLV infections is vaccination. Some marketed vaccines have limited efficacy. Moreover, there are FeLV-vaccines which in a minor number of cats can cause severe side effects like tumors at the injection site. The estimated average annual sales volume of FeLV-vaccines is fare above 50 million USD.

About MOLOGEN

MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

back to the overview